Literature DB >> 20096670

The expression profile of FRAT1 in human gliomas.

Geng Guo1, Xinggang Mao, Peng Wang, Bolin Liu, Xiang Zhang, Xiaofan Jiang, Chengliang Zhong, Junli Huo, Ji Jin, Yuzhen Zhuo.   

Abstract

FRAT1 was originally characterized as a protein frequently rearranged in advanced T cell lymphoma, which inhibits GSK-3-mediated phosphorylation of beta-catenin and positively regulates the Wnt signaling pathway. FRAT1 has been identified as a proto-oncogene involved in tumorigenesis. Previous studies have shown that FRAT1 is strikingly overexpressed in some human cancers. However, the relationship between FRAT1 and human gliomas is unclear. In this study, we detected the expression of FRAT1 in human gliomas by immunohistochemistry, Western blot and RT-PCR. FRAT1 was found to be specifically expressed in the majority of glioma samples, and their expression levels increased markedly with the increase of WHO grades. In addition, there was a positive correlation between FRAT1 immunoreactivity score (IRS) and beta-catenin IRS. Our results suggest that FRAT1 may be an important factor in the tumorigenesis and progression of gliomas, and could be used as a potential molecular marker for pathological diagnosis and a target for biological therapy. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20096670     DOI: 10.1016/j.brainres.2010.01.037

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  14 in total

1.  Overexpression of Frat1 correlates with malignant phenotype and advanced stage in human non-small cell lung cancer.

Authors:  Yong Zhang; Juan-Han Yu; Xu-Yong Lin; Yuan Miao; Yang Han; Chui-Feng Fan; Xin-Jun Dong; Shun-Dong Dai; En-Hua Wang
Journal:  Virchows Arch       Date:  2011-08-05       Impact factor: 4.064

Review 2.  Current Understanding on EGFR and Wnt/β-Catenin Signaling in Glioma and Their Possible Crosstalk.

Authors:  Indranil Paul; Seemana Bhattacharya; Anirban Chatterjee; Mrinal K Ghosh
Journal:  Genes Cancer       Date:  2013-11

3.  FRAT1 expression regulates proliferation in colon cancer cells.

Authors:  Kongxi Zhu; Jianqiang Guo; Hongjuan Wang; Weihua Yu
Journal:  Oncol Lett       Date:  2016-10-19       Impact factor: 2.967

4.  The clinical pathological significance of FRAT1 and ROR2 expression in cartilage tumors.

Authors:  L He; Z Yang; J Zhou; W Wang
Journal:  Clin Transl Oncol       Date:  2014-11-12       Impact factor: 3.405

5.  Silencing of FRAT1 by siRNA inhibits the proliferation of SGC7901 human gastric adenocarcinoma cells.

Authors:  Qinggong Yu; L U Shang; Hongbo Yu; Zirong Yang; Dekui Xu
Journal:  Biomed Rep       Date:  2016-01-11

6.  Expression of Frat1 correlates with expression of β-catenin and is associated with a poor clinical outcome in human SCC and AC.

Authors:  Yong Zhang; Yang Han; Rui Zheng; Juan-Han Yu; Yuan Miao; Liang Wang; En-Hua Wang
Journal:  Tumour Biol       Date:  2012-04-17

Review 7.  Wnt/beta-catenin signaling and small molecule inhibitors.

Authors:  Andrey Voronkov; Stefan Krauss
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  β-Catenin Signalling in Glioblastoma Multiforme and Glioma-Initiating Cells.

Authors:  Mireia Nager; Deepshikha Bhardwaj; Carles Cantí; Loreta Medina; Pere Nogués; Judit Herreros
Journal:  Chemother Res Pract       Date:  2012-02-12

9.  Overexpression of FRAT1 is associated with malignant phenotype and poor prognosis in human gliomas.

Authors:  Geng Guo; Cheng-liang Zhong; Yang Liu; Xing-gang Mao; Zheng Zhang; Ji Jin; Jing Liu; Liu Yang; Jin-ming Mao; Yu-hong Guo; Yuan-li Zhao
Journal:  Dis Markers       Date:  2015-04-02       Impact factor: 3.434

10.  Knockdown of FRAT1 expression by RNA interference inhibits human glioblastoma cell growth, migration and invasion.

Authors:  Geng Guo; Dong Kuai; Sang Cai; Naizhao Xue; Yueting Liu; Jiehe Hao; Yimin Fan; Ji Jin; Xinggang Mao; Bolin Liu; Chengliang Zhong; Xiang Zhang; Yi Yue; Xiaodong Liu; Ning Ma; Yuhong Guo
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.